Anacor Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ANACOR PHARMS INC, and what generic alternatives to ANACOR PHARMS INC drugs are available?
ANACOR PHARMS INC has two approved drugs.
There are four US patents protecting ANACOR PHARMS INC drugs.
There are one hundred and twenty-six patent family members on ANACOR PHARMS INC drugs in twenty-eight countries and seventeen supplementary protection certificates in fifteen countries.
Summary for Anacor Pharms Inc
International Patents: | 126 |
US Patents: | 4 |
Tradenames: | 2 |
Ingredients: | 2 |
NDAs: | 2 |
Drugs and US Patents for Anacor Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anacor Pharms Inc | KERYDIN | tavaborole | SOLUTION;TOPICAL | 204427-001 | Jul 7, 2014 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | 9,682,092*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | 8,168,614*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | 8,501,712*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | 8,039,451*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ANACOR PHARMS INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Topical Solution | 5% | ➤ Subscribe | 2018-07-09 |
International Patents for Anacor Pharms Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Portugal | 1853251 | ⤷ Try a Trial |
Japan | 2009531292 | ⤷ Try a Trial |
Hungary | E040060 | ⤷ Try a Trial |
South Africa | 200707408 | ⤷ Try a Trial |
Cyprus | 1116817 | ⤷ Try a Trial |
Israel | 193230 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Anacor Pharms Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2343304 | 2090017-1 | Sweden | ⤷ Try a Trial | PRODUCT NAME: CRISABOROLE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/19/1421 20200401 |
2343304 | 2020C/531 | Belgium | ⤷ Try a Trial | PRODUCT NAME: CRISABOROLE, OPTIONEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/19/1421 20200401 |
2343304 | PA2020524 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: KRISABOROLAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS FORMOJE; REGISTRATION NO/DATE: EU/1/19/1421 20200327 |
2343304 | C20200027 00352 | Estonia | ⤷ Try a Trial | PRODUCT NAME: KRISABOROOL;REG NO/DATE: EU/1/19/1421 01.04.2020 |
2343304 | 2020/024 | Ireland | ⤷ Try a Trial | PRODUCT NAME: CRISABOROLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/19/1421/001 EU/1/19/1421/004 20200327 |
2343304 | 122020000038 | Germany | ⤷ Try a Trial | PRODUCT NAME: CRISABOROL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON; REGISTRATION NO/DATE: EU/1/19/1421 20200327 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.